focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half

Thu, 26th Oct 2023 18:12

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Wednesday and Thursday, and not separately reported by Alliance News:

----------

Riverstone Credit Opportunities Income PLC - London-based energy infrastructure and energy transition credit investor - Net asset value at September 30 was USD1.07, unchanged from June 30. Says this stability was due to continued strong portfolio performance during the third quarter of 2023, and that as of September 30 it is nearly fully invested based on the revolving credit facility added in the fourth quarter last year and on current portfolio commitments. Riverstone Credit says it remains extremely well positioned due to its portfolio of accredited energy-transition focused investments through green or sustainability-linked structured loans. Notes "backdrop of strong energy market performance, the global focus on decarbonisation and the company's unique focus on short duration lending."

----------

Bloomsbury Publishing PLC - London-based publisher - Pretax profit for the half year ended August 31 was up 8% to GBP14.0 million from GBP12.9 million the year before. Says revenue increased 11% to GBP136.7 million from GBP122.9 million, and diluted earnings per share rose 11% to 13.66 pence from 12.30p. Consumer revenue grew 17% to GBP89.4 million, Adult Trade revenue rose 8% to GBP27.6 million and Children's Trade revenue grew 22% to GBP61.7 million. Declares interim dividend of 3.70p per share, more than double 1.41p the prior year. Cash at August 31 totalled GBP39.1 million, down from GBP41.5 million on the same day in 2022. Says it is confident it will achieve market expectations for the year ending February 29 2024, meaning revenue of GBP273.1 million and profit before tax and "highlighted items" of GBP32.5 million.

----------

Schroder Income Growth Fund PLC - UK-based investment company - Lifts dividend for the year ended August 31 by 4.6% to 13.80p per share from 13.20p the year before. Net asset value total return was positive 4.2%, underperforming against positive 5.2% from the FTSE All Share Total Return index. NAV per share decreased to 293.58p from 295.26p. Says many challenges "look set to continue into the year ahead."

----------

Haydale Graphene Industries PLC - Carmarthenshire, Wales-based technology solutions company - Pretax loss for the year ended June 30 widens to GBP6.6 million compared with GBP5.2 million the previous year. Revenue increased 48% to GBP4.3 million from GBP2.9 million, with US sales continuing to progress on "growth in the core aerospace and automotive markets". Administrative expenses increased 13% to GBP6.3 million from GBP5.5 million. Non-Executive Chair David Banks says: "We have made important progress in our next planned steps as a business by forging commercial partnerships and collaborations with leading organisations...the board remains confident that the company will be able to take advantage of the traction it is now seeing."

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that in six months ended July 31, pretax loss widened to GBP6.6 million from GBP4.5 million the previous year. Revenue fell 46% to GBP160,000 from GBP295,000. Chief Executive Officer Ali Mortazavi says: "Despite a severe macroeconomic climate, we have made significant progress during the past six months...we have been able to translate our computational analyses into tangible assets, generating compelling preclinical data at a fraction of the R&D spend of any competitor." Research & development expenditure increased to GBP5.3 million from GBP3.1 million. Company expects higher "underlying cash burn" in the current half year due to its "planned increase in R&D spend to continue the expansion of our AI capabilities and progress the identification and execution of preclinical targets, together with sustaining our active IP strategy as novel inventions are generated."

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
8 May 2014 10:51

e-Therapeutics Trading Up As Brain Cancer Trial To Resume Recruitment

LONDON (Alliance News) - Shares in e-Therapeutics PLC were trading higher Thursday after it said that it had been cleared by the US Food and Drug administration to resume recruiting patients for its Phase Ia study of compound ETS2101 in brain cancer. The company had previously paused recrui

Read more
7 Apr 2014 12:25

UPDATE: e-Therapeutics Appoints Steve Medlicott Chief Financial Officer

LONDON (Alliance News) - e-Therapeutics PLC Monday said that it had appointed Steve Medlicott as Chief Financial Officer, following the resignation of Daniel Elger with immediate effect, also announced Monday. Medlicott had advised the company on its GBP40 million fund-raising in 2013. Medl

Read more
7 Apr 2014 10:57

e-Therapeutics's Chief Financial Officer Daniel Elger Resigns

LONDON (Alliance News) - e-Therapeutics PLC Monday said that Daniel Elger has resigned as Chief Financial officer and a director of the company, with immediate effect. e-Therapeutics said that the company's finances will be managed on an interim basis by Paul Stockdale, who has been the com

Read more
31 Mar 2014 12:50

REPEAT: UK MIDDAY BRIEFING: Babcock JV Wins GBP7 Billion Nuclear Contract

LONDON (Alliance News) - Babcock International Group is leading the FTSE 100 higher Monday after its Cavendish Fluor Partnership joint venture was selected as the preferred bidder for a GBP7 billion nuclear plant decommissioning contract.

The joint venture with Fluo

Read more
31 Mar 2014 12:45

UK MIDDAY BRIEFING: Babcock JV Wins GBP7 Billion Nuclear Contract

LONDON (Alliance News) - Babcock International Group is leading the FTSE 100 higher Monday after its Cavendish Fluor Partnership joint venture was selected as the preferred bidder for a GBP7 billion nuclear plant decommissioning contract.

The joint venture with Flou

Read more
31 Mar 2014 10:35

UK WINNERS & LOSERS: Babcock Leads FTSE 100 Risers; Insurers Rebound

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.

-------

FTSE 100 - WINNERS

Babcock International Group, up 3.5%. The company said its Cavendish Fluor Partnership has

Read more
31 Mar 2014 08:33

e-Therapeutics Rises As It Gets Good Interim Drug Trial Results

LONDON (Alliance News) - e-Therapeutics PLC Monday said it had achieved positive interim results from a UK study evaluating the safety, dosing and anti-tumour activity of its ETS2101 drug in patients with advanced solid cancer tumours. In a statement, the company said that it had completed

Read more
26 Mar 2014 13:40

UK MIDDAY BRIEFING: Government Completes 2nd Lloyds Bank Stake Sale

LONDON (Alliance News) - The UK government has raised a further GBP4.20 billion from its second sale of Lloyds Banking Group PLC shares, meaning it has now recouped GBP7.41 billion of the roughly GBP21 million that taxpayers injected into the bank during the financial crisis.<

Read more
26 Mar 2014 11:30

UK WINNERS & LOSERS: Standard Life Leads FTSE 100 Risers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Wednesday.

-------

FTSE 100 - WINNERS

Standard Life, up 5.2%. The company has agreed to buy Ignis Asset Mana

Read more
26 Mar 2014 11:03

e-Therapeutics Gains As Recruitment For Cancer Trial Resumes

LONDON (Alliance News) - Shares in e-Therapeutics PLC jumped Wednesday morning after the biotechnology company said it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial. Recruitment for the trial was temporarily paused ov

Read more
24 Jan 2014 12:41

UK MIDDAY BRIEFING: Bank Of England Now Focused On Productivity

LONDON (Alliance News) - Bank of England Governor Mark Carney Friday signaled that rising productivity will now be the key factor that decides when the central bank will start to tighten monetary policy, and any tightening will be a slow, gradual process.

In a speech at the World Ec

Read more
24 Jan 2014 11:01

e-Therapeutics Temporarily Halts Recruitment In Trial Due To Drug Supply Issue

LONDON (Alliance News) - Shares in e-Therapeutics PLC dropped 16% Friday morning after it said that it was temporarily halting recruitment into its ETS2101 cancer trials due to a drug supply issue. e-Therapeutics said that there had been a practical issue with the stored drugs for the trial

Read more
24 Jan 2014 10:58

UK WINNERS & LOSERS: Cairn Falls As Indian Tax Department Gets In Touch

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday. ------- FTSE 100 - WINNERS Weir Group, up 0.2%. The engineering company said it had won a USD98 million, or GBP59 million, two-year contract to provide

Read more
7 Jan 2014 08:22

AIM IN BRIEF: H&T Says Profit As Expected, But Gold Price Has Hurt

Read more
31 Oct 2013 13:36

e-Therapeutics Starts Phase IIb Trial Of Depressive Disorder Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.